Tokyo, Oct 22, 2007 (JCN Newswire) - Chugai Pharmaceutical Co., Ltd. (TSE: 4519) announced today that erlotinib hydrochloride, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor [brand name: Tarceva(R) Tablet 25 mg, 100 mg and 150 mg (hereafter, Tarceva)], which was filed in April 14, 2006, obtained approval on October 19, 2007 from the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with nonresectable recurrent and advanced non-small cell lung cancer (NSCLC) which is aggravated following chemotherapy.
